Introducing New York Valves: The Structural Heart Summit
The Cardiovascular Research Foundation (CRF) is excited to introduce New York Valves: The Structural Heart Summit, the expanded next iteration of our renowned a
Stay updated with breaking news from Structural Heart. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Cardiovascular Research Foundation (CRF) is excited to introduce New York Valves: The Structural Heart Summit, the expanded next iteration of our renowned a
The Cardiovascular Research Foundation (CRF) is excited to introduce New York Valves: The Structural Heart Summit, the expanded next iteration of our renowned a
The Evolut FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the Evolut™ FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. The latest Evolut FX+ TAVR system maintains the valve performance benefits of the legacy Evolut TAVR platform and is designed to facilitate coronary access.
Medtronic announced that the FDA approved its next-generation Evolut FX+ transcatheter aortic valve replacement (TAVR) system.